(Q42879876)

9 November 2017

title

A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia (English)

1 reference

9 November 2017

A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia (English)

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

18 July 2024

0 references

Soamnauth Misir

3

1 reference

9 November 2017

Michael H. Davidson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20860413

18 July 2024

Joanne M. Donovan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20860413

18 July 2024

Michael R. Jones

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20860413

18 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20860413

18 July 2024

publication date

1 January 2010

1 reference

American journal of cardiovascular drugs

9 November 2017

published in

1 reference

9 November 2017

volume

10

1 reference

9 November 2017

issue

5

1 reference

9 November 2017

page(s)

305-314

1 reference

Prediction of Coronary Heart Disease Using Risk Factor Categories

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11584310-000000000-00000

Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584310-000000000-00000

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

21 January 2018

1

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial

18 July 2024

3

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

18 July 2024

4

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

18 July 2024

6

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

18 July 2024

7

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

The value of lowering cholesterol after myocardial infarction

18 July 2024

8

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

18 July 2024

10

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

18 July 2024

11

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

18 July 2024

14

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

18 July 2024

15

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

18 July 2024

16

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia

18 July 2024

17

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease

18 July 2024

18

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs

18 July 2024

19

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

18 July 2024

20

1 reference

https://api.crossref.org/works/10.2165/11584310-000000000-00000

18 July 2024

Identifiers

1 reference

Dimensions Publication ID

9 November 2017

1038369869

0 references

1 reference